Mackenzie Financial Corp raised its position in shares of Danaher Co. (NYSE:DHR - Free Report) by 47.2% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,666,144 shares of the conglomerate's stock after buying an additional 534,335 shares during the quarter. Mackenzie Financial Corp owned 0.23% of Danaher worth $382,463,000 at the end of the most recent quarter.
A number of other hedge funds also recently bought and sold shares of DHR. Kentucky Retirement Systems Insurance Trust Fund increased its holdings in shares of Danaher by 11.6% in the 4th quarter. Kentucky Retirement Systems Insurance Trust Fund now owns 21,233 shares of the conglomerate's stock valued at $4,874,000 after purchasing an additional 2,202 shares during the period. FAS Wealth Partners Inc. increased its holdings in shares of Danaher by 20.6% in the 4th quarter. FAS Wealth Partners Inc. now owns 9,597 shares of the conglomerate's stock valued at $2,203,000 after purchasing an additional 1,639 shares during the period. Generate Investment Management Ltd acquired a new position in shares of Danaher in the 4th quarter valued at about $8,044,000. Compass Capital Management Inc. increased its holdings in shares of Danaher by 4.8% in the 4th quarter. Compass Capital Management Inc. now owns 237,922 shares of the conglomerate's stock valued at $54,615,000 after purchasing an additional 10,994 shares during the period. Finally, Channing Global Advisors LLC increased its holdings in shares of Danaher by 42.8% in the 4th quarter. Channing Global Advisors LLC now owns 5,666 shares of the conglomerate's stock valued at $1,301,000 after purchasing an additional 1,698 shares during the period. 79.05% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
A number of equities analysts recently commented on the company. Robert W. Baird dropped their price objective on Danaher from $231.00 to $225.00 and set an "outperform" rating on the stock in a report on Wednesday, April 23rd. Royal Bank of Canada restated an "outperform" rating and issued a $250.00 price objective on shares of Danaher in a report on Wednesday, April 23rd. Barclays increased their price objective on Danaher from $205.00 to $215.00 and gave the stock an "overweight" rating in a report on Tuesday, April 22nd. Jefferies Financial Group dropped their price objective on Danaher from $260.00 to $230.00 and set a "buy" rating on the stock in a report on Tuesday, April 22nd. Finally, HSBC dropped their price objective on Danaher from $270.00 to $240.00 in a report on Friday, April 25th. Five investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $263.24.
View Our Latest Stock Analysis on DHR
Insider Activity
In other Danaher news, EVP Christopher Paul Riley sold 15,805 shares of Danaher stock in a transaction on Wednesday, April 30th. The shares were sold at an average price of $198.00, for a total transaction of $3,129,390.00. Following the sale, the executive vice president now owns 15,179 shares in the company, valued at $3,005,442. The trade was a 51.01% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Chairman Steven M. Rales sold 1,250,000 shares of Danaher stock in a transaction on Monday, May 12th. The stock was sold at an average price of $196.74, for a total transaction of $245,925,000.00. Following the sale, the chairman now owns 3,105,808 shares in the company, valued at $611,036,665.92. This represents a 28.70% decrease in their position. The disclosure for this sale can be found here. 11.10% of the stock is owned by company insiders.
Danaher Stock Performance
Shares of DHR traded up $4.48 during mid-day trading on Tuesday, hitting $189.02. The company's stock had a trading volume of 2,990,603 shares, compared to its average volume of 3,473,399. Danaher Co. has a one year low of $171.00 and a one year high of $281.70. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.40. The firm has a market capitalization of $135.28 billion, a PE ratio of 35.80, a price-to-earnings-growth ratio of 2.66 and a beta of 0.80. The stock's 50-day moving average is $194.50 and its two-hundred day moving average is $214.85.
Danaher (NYSE:DHR - Get Free Report) last posted its quarterly earnings data on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share for the quarter, beating the consensus estimate of $1.62 by $0.26. Danaher had a return on equity of 10.82% and a net margin of 16.33%. The company had revenue of $5.74 billion during the quarter, compared to analysts' expectations of $5.58 billion. As a group, sell-side analysts anticipate that Danaher Co. will post 7.63 EPS for the current year.
Danaher Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be given a $0.32 dividend. This represents a $1.28 annualized dividend and a dividend yield of 0.68%. Danaher's dividend payout ratio is 24.85%.
About Danaher
(
Free Report)
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Featured Stories
Before you consider Danaher, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Danaher wasn't on the list.
While Danaher currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
